Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Promis Neurosciences Inc (OTC: ARFXF).

Full DD Report for ARFXF

You must become a subscriber to view this report.


Recent News from (OTC: ARFXF)

ProMIS Neurosciences Announces First Quarter 2018 Results
ProMIS Neurosciences Announces First Quarter 2018 Results Canada NewsWire TORONTO and CAMBRIDGE, MA, May 11, 2018 TORONTO and CAMBRIDGE, MA , May 11, 2018 /CNW/  -  ProMIS Neurosciences Inc. ("ProMIS" or the "Company"), a company focused on the discovery and d...
Source: Canada Newswire
Date: May, 11 2018 07:30
ProMIS Neurosciences Closes $7.2 Million Private Placement
TORONTO and CAMBRIDGE, MA , May 1, 2018 /PRNewswire/ - ProMIS Neurosciences Inc. (TSX:PMN; OTCQB:ARFXF) is pleased to announce that it closed yesterday a private placement of 19,306,668 Units at the price of CDN$0.375 per Unit for gross proceeds of approximately CDN$ 7,240,...
Source: PR Newswire
Date: May, 01 2018 07:30
ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease
Scientific Publication Describes One of Six Distinct Therapeutic Targets on Toxic Prion-Like Amyloid Beta Oligomers TORONTO and CAMBRIDGE, MA , April 10, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision t...
Source: PR Newswire
Date: April, 10 2018 07:30
ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing Canada NewsWire TORONTO and CAMBRIDGE, MA, April 3, 2018 Both new appointees bring over 30 years of successful drug development experie...
Source: Canada Newswire
Date: April, 03 2018 07:30
ProMIS Neurosciences (ARFXF) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - Slideshow
The following slide deck was published by Promis Neurosciences Inc in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 26 2018 14:50
ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board
TORONTO and CAMBRIDGE, MA , March 20, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Sharon Cohen , MD, to the Company's scientif...
Source: PR Newswire
Date: March, 20 2018 07:30
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results
TORONTO and CAMBRIDGE, MA , March 14, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the year ended Decembe...
Source: PR Newswire
Date: March, 14 2018 07:30
ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants Canada NewsWire TORONTO and CAMBRIDGE, MA, March 7, 2018 TORONTO and CAMBRIDGE, MA , March 7, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company fo...
Source: Canada Newswire
Date: March, 07 2018 07:30
ProMISA recieves proceeds of warrants exercise
ProMISA recieves proceeds of warrants exercise
Source: OTC Markets
Date: March, 07 2018 00:00

 


About Promis Neurosciences Inc (OTC: ARFXF)

Logo for Promis Neurosciences Inc (OTC: ARFXF)

ProMIS Neuorsciences Inc is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimers disease AD and amyotrophic lateral sclerosis ALS .

 

 

 

Current Management

  • Elliot Goldstein / CEO, President
  • Steven Plotkin / Officer
  • Daniel E. Geffken / CFO
  • Johanne Kaplan / Chief Development Officer
  • Neil Cashman / Chief Scientific Officer
  • Kristi Lanier / Director, Fin.
  • Eugene Williams / Executive Chairman
  • Anthony J Giovinazzo / Independent Director, Audit Committee Member, Compensation Committee Member
  • Richard Gregory / Independent Director, Compensation Committee Member
  • Patrick Kirwin / Independent Director, Audit Committee Member
  • Johannes Minho Roth / Independent Director
  • William Wyman / Independent Director, Audit Committee Member, Compensation Committee Member

Current Share Structure

  • Market Cap: $70,856,647 - 03/12/2018
  • Issue and Outstanding: 220,058,534 - 11/08/2017

 


Recent Filings from (OTC: ARFXF)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 03 2018
Proxy Materials - Form of Proxy - 2016
Filing Type: Proxy Materials - Form of Proxy - 2016Filing Source: OTC Markets
Filing Date: November, 14 2017
OTCQB Certification - Certification
Filing Type: OTCQB Certification - CertificationFiling Source: OTC Markets
Filing Date: November, 14 2017
Notice of Change in Substantial Holder Interest - Early warning report 08122016
Filing Type: Notice of Change in Substantial Holder Interest - Early warning report 08122016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Shareholders rights Plan 01222016
Filing Type: Supplemental Information - Shareholders rights Plan 01222016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 08302017
Filing Type: Supplemental Information - Material Change report 08302017Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 08102017
Filing Type: Supplemental Information - Material Change report 08102017Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 05132016
Filing Type: Supplemental Information - Material Change report 05132016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 04052016
Filing Type: Supplemental Information - Material Change report 04052016Filing Source: OTC Markets
Filing Date: November, 14 2017
Proxy Statement - Mgmt information Circular 2016
Filing Type: Proxy Statement - Mgmt information Circular 2016Filing Source: OTC Markets
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: ARFXF)

Daily Technical Chart for (OTC: ARFXF)


Stay tuned for daily updates and more on (OTC: ARFXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARFXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARFXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ARFXF and does not buy, sell, or trade any shares of ARFXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/